TH588 hydrochloride

TH588 hydrochloride 是一种高选择性人源 MTH1 抑制剂(IC50=5 nM),兼具微管靶向特性,可干扰有丝分裂进程,诱导基因组 8-oxodG 形成、DNA 损伤及细胞周期阻滞,表现出显著细胞毒性,与异硫氰酸苯乙酯联用可增强 ROS 介导的效应,并能有效抑制小鼠体内恶性黑色素瘤内脏转移灶的生长,可广泛应用于癌症、胰腺癌、白血病、淋巴瘤、恶性黑色素瘤及肺癌等相关研究。
产品编号: MS-H25322 CAS No.: 1640282-30-9 分子式: C13H13Cl3N4 分子量: 331.63
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TH588 hydrochloride 是一种高选择性人源 MTH1 抑制剂(IC50=5 nM),兼具微管靶向特性,可干扰有丝分裂进程,诱导基因组 8-oxodG 形成、DNA 损伤及细胞周期阻滞,表现出显著细胞毒性,与异硫氰酸苯乙酯联用可增强 ROS 介导的效应,并能有效抑制小鼠体内恶性黑色素瘤内脏转移灶的生长,可广泛应用于癌症、胰腺癌、白血病、淋巴瘤、恶性黑色素瘤及肺癌等相关研究。

生物实验数据

生物活性 TH588 hydrochloride is a highly selective human MTH1 inhibitor (IC50=5 nM) that also exhibits microtubule-targeting properties, interferes with mitotic progression, induces genomic 8-oxodG formation, DNA damage, and cell cycle arrest, and displays significant cytotoxicity; when combined with phenethyl isothiocyanate, it enhances ROS-mediated effects and effectively inhibits the growth of visceral metastatic lesions of malignant melanoma in mice, and it can be widely applied in research related to cancer, pancreatic cancer, leukemia, lymphoma, malignant melanoma, and lung cancer.
体外研究
(In Vitro)

TH588 hydrochloride (1-2 µM; 72 h) 可降低强力霉素诱导的 A2780 Pol δ 替换细胞的活力,且在表达易错型或双突变体 Pol δ 变体的细胞中具有显著更强的细胞毒性。
TH588 hydrochloride (1 µM; 24 h) 在强力霉素诱导的 A2780 Pol δ 替换细胞中诱导切割型 PARP 信号通路激活,且在表达易错型 Pol δ 变体的细胞中,该信号水平显著更高。
TH588 hydrochloride (2 µM; 24 h) 可在强力霉素诱导的 A2780 Pol δ 替换细胞中诱导半胱天冬酶介导的细胞凋亡,且表达易错型 Pol δ 变体的细胞凋亡水平显著更高。
TH588 hydrochloride (5 µM; 16 h) 在与 RO3306 预孵育后可诱导 U2OS 细胞发生有丝分裂期 DNA 复制,导致带有 EdU 灶的有丝分裂细胞数量显著增加。
TH588 hydrochloride (0.1-10 µM; 72 h) 以剂量依赖方式降低 U2OS 细胞的存活率,且这种细胞毒性可通过与 reversine 联合处理完全消除。
TH588 hydrochloride (2-6 μM; 5 d) 可在 5 天内浓度依赖性地抑制人胰腺癌 Panc-1 细胞的生长,且该作用不依赖于氧化应激。
TH588 hydrochloride (1-3 μM; 7 d) 可显著增强 H2O2 诱导的人胰腺癌 Panc-1 细胞在 7 天内的生长抑制作用,尽管单独使用时对细胞生长无影响。
TH588 hydrochloride (1-3 μM; 5 d) 可显著增强阿霉素对人胰腺癌 MIAPaCa-2 细胞的生长抑制作用,作用时长超过 5 天。
TH588 hydrochloride (1-3 μM; 5 d) 可显著增强 PEITC 对人胰腺癌 MIAPaCa-2 细胞的生长抑制作用,且该联合用药的疗效优于其他 ROS 诱导剂与 TH588 的组合。
TH588 hydrochloride (2 μM; 2 d) 与 4 μM PEITC 联合作用,可在 2 天内诱导人胰腺癌 MIAPaCa-2 细胞发生 caspase 依赖性细胞死亡。
TH588 hydrochloride (0.2-0.6 μM; 5 d) 可显著增强 PEITC 对人白血病 NB4 细胞的生长抑制作用,作用时长超过 5 天,且不受 MTH1 mRNA 表达水平相对较低的影响。
TH588 hydrochloride (0.2-0.6 μM; 5 d) 可显著增强 PEITC 对人淋巴瘤 BALM3 细胞的生长抑制作用,作用时长超过 5 天。
TH588 hydrochloride (1-2 μM; 56 h) 可在孵育 56 小时后诱导人胰腺癌 MIAPaCa-2 细胞中 8-oxo-dG 和 pH2AX (氧化性 DNA 损伤标志物) 的核内形成。
TH588 hydrochloride (0.4 μM; 56 h) 与 2 μM PEITC 联合作用,在孵育 56 小时后可协同诱导人胰腺癌细胞 MIAPaCa-2 中 8-oxo-dG 和 γH2AX 灶的核内形成。
TH588 hydrochloride (1-8 µM; 2 h) 可浓度依赖性地破坏非同步化有丝分裂 H460 人肺癌细胞的中心体分离、纺锤体双极性及染色体列队,其中 4 µM 浓度可使超过 50%的有丝分裂细胞产生单极纺锤体。
TH588 hydrochloride (4-6 µM; 24 h) 可诱导人肺癌 H460 细胞发生 G2/M 期细胞周期阻滞,其中 4 µM 浓度可使 G2/M 期细胞占比升高至约 42%,6 µM 浓度可使该占比升高至约 35%。
TH588 hydrochloride (4-7 µM; 48 h) 可浓度依赖性地诱导人肺癌 H460 细胞发生 G1 期阻滞,并抑制细胞周期重进入;其中 7 µM 浓度可使约 70%的细胞发生 G1 期阻滞。
TH588 hydrochloride (6 µM; 48 h) 研究表明,TP53 和 USP28 是 TH588 诱导人肺癌 H460 细胞发生 G1 期阻滞所必需的,敲除 TP53 可使 6 µM TH588 诱导的 G1 期阻滞比例从约 40% 降至约 10%。
TH588 hydrochloride (2-8 µM; 24 h) 可浓度依赖性地升高人肺癌 H460 细胞中的 p53 水平,且该激活作用依赖于 USP28,因为 USP28 敲除克隆未出现 p53 诱导。

Immunofluorescence

Cell Line: U2OS cells
Concentration: 5 µM
Incubation Time: 16 h
Result: Induced EdU foci in mitotic cells, indicating mitotic DNA replication.
Showed significantly higher percentage of mitotic cells with EdU foci in TH588-treated cells compared to control cells, though lower than the positive control aphidicolin-treated cells.

Cell Viability Assay

Cell Line: U2OS cells
Concentration: 0.1-10 µM
Incubation Time: 72 h
Result: Reduced cell viability in a dose-dependent manner, with viability dropping to ~15% at 10 µM TH588.
Showed co-treatment with reversine completely abrogated TH588-induced cytotoxicity, maintaining viability at ~100% across all TH588 concentrations tested.

Cell Proliferation Assay

Cell Line: human pancreatic cancer MIAPaCa-2 cells
Concentration: 1-3 μM
Incubation Time: 5 days
Result: Significantly enhanced doxorubicin-induced growth inhibition of MIAPaCa-2 cells.\nHardly affected MIAPaCa-2 cell growth when used alone at 1 μM.
Significantly enhanced PEITC-induced growth inhibition.
Formed the most effective growth-inhibiting combination with PEITC among tested ROS inducer pairings.

Immunofluorescence

Cell Line: unsynchronized H460 human lung cancer cells
Concentration: 1-8 µM
Incubation Time: 2 hours
Result: Caused concentration-dependent decreases in centrosome separation, with reduced separation at all tested concentrations.
Induced monopolar spindles and uncongressed chromosomes in over 50% of mitotic cells at 4 µM; higher concentrations increased the proportion of these abnormalities.
Did not affect centrosome duplication or the localization of aurora kinase A, polo-like kinase 1, or kinesin family member 23.

Cell Proliferation Assay

Cell Line: USP28-knockout, TP53-knockout, and control H460 human lung cancer cells
Concentration: 4-7 µM
Incubation Time: 3 days followed by 12 days drug-free
Result: USP28-knockout clones showed significantly increased colony formation at all tested concentrations compared to controls, with 7 µM treatment yielding ~40% of DMSO control colonies (compared to ~5% for controls).
TP53-knockout clones also showed increased colony formation at all concentrations, with 7 µM treatment yielding ~5% of DMSO control colonies (compared to ~5% for controls, with three TP53 knockout clones showing stronger rescue than controls).

Cell Cycle Analysis

Cell Line: H460 human lung cancer cells
Concentration: 4-7 µM
Incubation Time: 48 total hours (final 24 hours including EdU)
Result: Increased the proportion of G1-arrested, EdU-negative cells in a concentration-dependent manner: 4 µM induced ~20% G1 arrest, 5 µM ~40%, 6 µM ~60%, and 7 µM ~70%.
Saw over 98% of DMSO-treated cells were EdU-positive and re-entered the cell cycle, while TH588 treatment also induced a small sub-G1 apoptotic population at higher concentrations.

Cell Cycle Analysis

Cell Line: USP28-knockout, TP53-knockout, and control H460 human lung cancer cells
Concentration: 6 µM
Incubation Time: 48 total hours (final 24 hours including EdU)
Result: TP53-knockout clones showed a marked reduction in G1-arrested, EdU-negative cells (from ~40% in controls to ~10%) and a corresponding increase in EdU-positive cells (from ~55% in controls to ~85%).
USP28-knockout clones showed a weaker but significant reduction in G1-arrested cells (from ~40% in controls to ~30%) and increase in EdU-positive cells (from ~55% in controls to ~65%).
体内研究
(In Vivo)

TH588 hydrochloride 可增强 8-oxodGTP (MS-A81563) 诱导的斑马鱼胚胎毒性,尤其在缺乏 MTH1 的情况下。

Animal Model: 5-6 weeks female SCID mice (SW480 xenograft cancer model)
Dosage: 30 mg/kg
Administration: Subcutaneous injection (s.c.); once daily for 35 days
Result: Reduced tumour growth in SW480 xenograft cancer model.

化学信息

分子量 331.63
分子式 C13H13Cl3N4
CAS No. 1640282-30-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础